PIK3CA and neoplasm of oropharynx: PIK3CA amplification (but not PIK3CA mutation) was associated with poorer progression-free survival (PFS), while RAS mutations were associated with poorer PFS and overall survival (OS) in a series enriched in patients with oropharyngeal tumors.